세계의 동물용 백신 시장(-2029년) : 유형별(돼지, 가금, 가축, 반려동물), 기술별(약독화, 불활화, 톡소이드), 투여 경로별(근육내, 피하, 경구), 최종사용자별(병원, 클리닉)

Veterinary Vaccines Market by Type (Porcine, Poultry, Livestock, Companion Animals), Technology (Live Attenuated, Inactivated, Toxoid), Route of Administration (Intramuscular, Subcutaneous, Oral), End user (Hospitals, Clinics) - Global Forecast to 2029

US $ 4,950 ￦ 7,151,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,607,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,775,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 14,448,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

동물용 백신 시장 규모는 2024년 93억 9,000만 달러에서 예측 기간 동안 CAGR 6.1%(연평균 6.00%)로 2029년에는 133억 3,000만 달러에 달할 것으로 예상됩니다.

조사 범위
조사 대상 연도	2024-2029년
기준 연도	2023년
예측 기간	2024-2029년
검토 단위	금액(달러)
부문별	유형별, 질환별, 기술별, 투여 경로별, 최종사용자별
대상 지역	북미, 유럽, 아시아태평양, 중동 및 아프리카

동물 건강에 대한 인식이 높아지고 반려동물 인구의 증가와 반려동물 사육률의 증가가 동물용 백신의 채택을 촉진하고 있습니다. 동물 건강 증진을 위한 정부의 노력과 반려동물 보험의 보급도 이러한 추세에 기여하고 있습니다. 북미와 유럽 등 주요 시장에서는 최근 반려동물에 대한 지출이 크게 증가함에 따라 많은 보호자들이 반려동물 보험에 가입하고 있습니다. 또한, 신흥 경제 국가들의 동물용 백신 보급과 새로운 첨단 백신 제품 개발에 대한 관심도 시장 성장을 더욱 촉진할 것으로 예상됩니다. 반면, 백신과 관련된 높은 비용성은 시장 확대에 있어 장애요인이 될 수 있습니다.

유형별로는 가축 백신 부문이 예측 기간 동안 가장 높은 점유율을 보일 것으로 예상됩니다. 동물성 식품에 대한 전 세계 수요가 증가하고, 증가하는 인구의 영양 요구를 충족시키기 위해 축산업이 강화되면서 동물의 건강 유지, 질병 발생 예방, 생산성 향상에 대한 중요성이 강조되고 있습니다. 또한, 정부 규제, 동물 건강에 대한 인식의 증가, 보다 안전하고 질병 없는 식품에 대한 수요 증가 등도 가축용 백신의 채택을 촉진하여 시장에서의 압도적인 점유율에 더욱 기여하고 있습니다.

투여 경로별로는 근육 내 투여 부문이 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 피하 백신이나 경구 백신과 같은 기존 투여 방식에 비해 근육 내 직접 투여되는 이 유형의 백신은 더 빠르고 강력한 면역 반응을 가능하게 합니다. 근육 내 백신은 장기적인 면역 생산이 가능하기 때문에 세균, 바이러스, 기생충 감염 등 다양한 질환의 치료에 자주 사용되고 있습니다. 근육 내 백신의 시장 점유율 확대는 효과가 입증되고, 사용이 간편하며, 수의사들이 반려동물의 개별 치료와 대규모 축산 모두에서 이 접근법을 선호하게 된 데에 기인합니다.

아시아태평양은 동물용 백신 시장에서 가장 빠르게 성장하고 있습니다. 특히 중국, 인도, 일본과 같은 경제권에서는 반려동물 양육 인구의 증가가 동물 의료 및 백신 접종에 대한 수요를 증가시키는 주요 요인으로 작용하고 있습니다. 또한, 이 지역에서는 동물의 건강과 예방책에 대한 인식이 높아지면서 예방접종에 대한 투자를 장려하고 있습니다. 가축 건강에 대한 관심 증가, 더 나은 수의학 시설, 경제 성장 등의 요인도 시장 성장에 크게 기여하고 있습니다. 정부 및 단체들은 동물 건강을 위한 노력을 지원하고 있으며, 가처분 소득이 증가함에 따라 더 많은 소비자들이 반려동물의 건강 관리를 개선하고자 하는 경향이 있습니다. 아시아태평양은 이러한 다양한 요인들이 복합적으로 작용하여 동물용 백신 시장의 중요한 성장 동력이 되고 있습니다.

세계의 동물용 백신 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 각종 영향요인 분석, 기술·특허 동향, 법·규제 환경, 사례 분석, 시장 규모 추정 및 예측, 각종 부문별·지역별 상세 분석, 경쟁 환경, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 소개

제2장 조사 방법

제3장 주요 요약

제4장 주요 인사이트

제5장 시장 개요

• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
• 업계 동향
• 기술 분석
• 고객의 사업에 영향을 미치는 동향/디스럽션
• 공급망 분석
• 밸류체인 분석
• 무역 분석
• Porter's Five Forces 분석
• 주요 이해관계자와 구입 기준
• 규제 분석
• 특허 분석
• 가격 분석
• 주요 회의와 이벤트
• 생태계 분석
• 사례 연구 분석
• 상환 분석
• 미충족 수요/최종사용자 기대
• AI/생성형 AI가 동물용 백신 시장에 미치는 영향
• 투자와 자금 조달 시나리오
• 파이프라인 분석

제6장 동물용 백신 시장 : 유형별

• 가축 백신
  • 우백신
  • 소형 반추동물 백신
• 돼지 백신
• 가금류 백신
• 반려동물 백신
  • 개용 백신
  • 고양이 백신
• 수산양식 백신
• 기타

제7장 동물용 백신 시장 : 질병별

• 가축
  • 소
  • 소형 반추동물
• 돼지
• 가금
• 반려동물
  • 개
  • 고양이
• 수산양식
• 기타

제8장 동물용 백신 시장 : 기술별

• 생약독화 백신
• 불활화 백신
• 톡소이드 백신
• 재조합 백신
• 기타

제9장 동물용 백신 시장 : 투여 경로별

• 피하
• 근육내
• 경구
• 비강내/스프레이
• 안내
• 기타

제10장 동물용 백신 시장 : 최종사용자별

• 수의 병원
• 수의 클리닉
• 기타

제11장 동물용 백신 시장 : 지역별

• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국
  • 뉴질랜드
  • 기타
• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 네덜란드
  • 기타
• 라틴아메리카
  • 브라질
  • 멕시코
  • 기타
• 중동 및 아프리카
  • GCC 국가
  • 기타

제12장 경쟁 구도

• 주요 진출 기업 전략/강점
• 매출 분석
• 시장 점유율 분석
• 기업 평가 매트릭스 : 주요 기업
• 기업 평가 매트릭스 : 스타트업/중소기업
• 브랜드/제품 비교
• 주요 기업 연구개발비
• 기업 평가와 재무 지표
• 경쟁 시나리오

제13장 기업 개요

• 주요 기업
  • MERCK & CO., INC.
  • ZOETIS
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • ELANCO
  • CEVA
  • VIRBAC
  • PHIBRO ANIMAL HEALTH CORPORATION
  • HESTER BIOSCIENCES LIMITED
  • NEOGEN CORPORATION
  • HIPRA
  • BIOGENESIS BAGO
  • TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.
  • CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.
  • JINYU BIO-TECHNOLOGY CO., LTD.
  • VAXXINOVA INTERNATIONAL B.V.
• 기타 기업
  • ENDOVAC ANIMAL HEALTH
  • BRILLIANT BIO PHARMA
  • APTIMMUNE
  • INDIAN IMMUNOLOGICALS LTD.
  • TORIGEN PHARMACEUTICALS INC.
  • INTAS PHARMACEUTICALS LTD.
  • OUROFINO ANIMAL HEALTH
  • BIOVAC LTD.
  • LABORATOIRE LCV
  • KYORITSU SEIYAKU CORPORATION

제14장 부록

KSM

영문 목차

영문목차

The veterinary vaccines market is projected to reach USD 13.33 billion by 2029, from USD 9.39 billion in 2024, at a CAGR of 6.1%." during the forecast period.

Scope of the Report
Years Considered for the Study	2024-2029
Base Year	2023
Forecast Period	2024-2029
Units Considered	Value (USD)
Segments	By type, disease, technology, route of administration, end user
Regions covered	North America, Europe, APAC, LATAM, and MEA

The growing awareness of animal health, along with the rising pet population and pet ownership, is driving the adoption of veterinary vaccines. Government initiatives aimed at improving animal health and the increasing uptake of pet insurance policies are also contributing to this trend. In major markets like North America and Europe, many pet owners are purchasing pet insurance due to the significant rise in pet care spending in recent years. Additionally, the focus on developing new and advanced vaccine products, combined with the growing adoption of veterinary vaccines in emerging economies, is expected to further support market growth. However, the high costs associated with vaccines may pose a challenge to the veterinary vaccines market's expansion.

"The livestock vaccines segment of veterinary vaccines market to register highest share during the forecast period."

Based on type, the livestock vaccines segment accounted for the largest share. As livestock animals are owned for the production of food, such as meat and dairy products. As global demand for animal derived food increases and livestock farming intensifies to meet the nutritional needs of an expanding population, there is a greater emphasis on maintaining animal health, preventing disease outbreaks, and improving productivity. Additionally, government regulations, rising awareness about animal health, and growing demand for safer, disease-free food products are driving the adoption of livestock vaccines, further contributing to their dominant share in the market.

"The intramuscular segment to capture the largest market share of veterinary vaccines market."

Based on route of administration, intramuscular vaccines hold a higher share in the veterinary vaccines market due to their effectiveness and widespread use. Compared to conventional methods of administration like subcutaneous or oral vaccines, this kind of vaccine is delivered directly into the muscle, enabling a faster and more powerful immune response. Because of their ability to produce long-lasting immunity, intramuscular vaccines are frequently used to treat a range of conditions, including bacterial, viral, and parasite infections. The increased market share of intramuscular vaccines is partly a result of their shown efficacy, simplicity of use, and veterinarians' inclination for this approach in both individual pet care and large-scale farming.

"Asia pacific accounted for the fastest growing region of the veterinary vaccines market by region."

The global veterinary vaccines market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the fastest growing market for veterinary vaccines. The increased ownership of pets is a major factor driving the need for veterinary care and vaccinations, particularly in economies like China, India, and Japan. Pet owners are also being encouraged to invest in vaccinations as a result of the region's increasing awareness of animal health and preventative measures. Growing focus on livestock health, better veterinary facilities, and economic expansion all contribute significantly to the market's growth. Governments and organizations have backed animal health initiatives, and more consumers are looking for improved pet healthcare as disposable incomes rise. The Asia Pacific region is becoming a significant growth engine for the veterinary vaccines market due to this confluence of variables.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-35%, Tier 2-40%, and Tier 3- 25%
• By Designation: Directors-25%, Managers-50% and Others-25%
• By Region: North America-35%, Europe-30%, Asia Pacific-15% and RoW-20%

The major players operating in the veterinary vaccines market market are Zoetis(US), Merck & Co, Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco (US), Virbac (France), Ceva (France), Phibro Animal Health Corporation (US), Hester Biosciences Limited (India), Neogen Corporation (US), HIPRA (Spain), Biogenesis Bago (Argentina), Tianjin Ringpu BioTechnology Co., Ltd. (China), China Animal Husbandry Industry Co., LTD. (China), Jinyu Bio-technology Co., Ltd. (China), and Vaxxinova International B.V.(Netherlands).

Research Coverage

This report studies the veterinary vaccines market based on type, disease, technology, route of administration and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

• Analysis of Key divers (increased companion animal population and pet ownership, growing incidence of infectious disease, government initiatives to improve animal health), restraints (high cost associated with vaccines), Opportunities (emerging markets, technological advancement and developments) , Challenge (limited awareness and shortage of veterinarians, stringent regulatory requirements)
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the veterinary vaccines market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the veterinary vaccines market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the veterinary vaccines market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & GEOGRAPHICAL SPREAD
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key secondary sources
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Objectives of primary research
    • 2.1.2.3 Key data from primary sources
    • 2.1.2.4 Key industry insights
    • 2.1.2.5 Breakdown of primaries
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS)
  • 2.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
  • 2.2.3 TOP-DOWN APPROACH
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ANALYSIS
• 2.5 STUDY ASSUMPTIONS
• 2.6 RISK ASSESSMENT
• 2.7 RESEARCH LIMITATIONS
  • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.7.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 VETERINARY VACCINES MARKET OVERVIEW
• 4.2 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY AND COUNTRY (2023)
• 4.3 VETERINARY VACCINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rise in companion animal population and pet ownership
    • 5.2.1.2 Increasing incidence of infectious zoonotic diseases
    • 5.2.1.3 Favorable initiatives by government agencies and animal associations
    • 5.2.1.4 Growing demand for animal-derived food products
    • 5.2.1.5 Increased adoption of pet insurance and high animal health expenditure
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of vaccine development
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Technological advancements for veterinary vaccine development
    • 5.2.3.2 Untapped growth potential in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Limited awareness about animal vaccines and shortage of trained veterinarians in low-income countries
    • 5.2.4.2 Stringent regulatory requirements for licensing veterinary vaccines
• 5.3 INDUSTRY TRENDS
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Recombinant DNA technology
    • 5.4.1.2 mRNA-based vaccines
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Vaccine adjuvant technology
    • 5.4.2.2 Needle-free and microneedle technology
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Genome editing technology
• 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 VALUE CHAIN ANALYSIS
• 5.8 TRADE ANALYSIS
  • 5.8.1 IMPORT DATA FOR HS CODE 300242
  • 5.8.2 EXPORT DATA FOR HS CODE 300230
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 THREAT OF SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF SUPPLIERS
  • 5.9.4 BARGAINING POWER OF BUYERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.10.2 KEY BUYING CRITERIA
• 5.11 REGULATORY ANALYSIS
  • 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.11.2 REGULATORY FRAMEWORK
    • 5.11.2.1 North America
      • 5.11.2.1.1 US
    • 5.11.2.2 Europe
    • 5.11.2.3 Rest of the World
      • 5.11.2.3.1 China
      • 5.11.2.3.2 Brazil
      • 5.11.2.3.3 Australia
• 5.12 PATENT ANALYSIS
  • 5.12.1 JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.13 PRICING ANALYSIS
  • 5.13.1 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY KEY PLAYER, 2021-2023
  • 5.13.2 AVERAGE SELLING PRICE TREND, BY REGION, 2021-2023
• 5.14 KEY CONFERENCES & EVENTS, 2024-2026
• 5.15 ECOSYSTEM ANALYSIS
• 5.16 CASE STUDY ANALYSIS
• 5.17 REIMBURSEMENT ANALYSIS
• 5.18 UNMET NEEDS/END-USER EXPECTATIONS
• 5.19 IMPACT OF AI/GEN AI ON VETERINARY VACCINES MARKET
• 5.20 INVESTMENT & FUNDING SCENARIO
• 5.21 PIPELINE ANALYSIS

6 VETERINARY VACCINES MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 LIVESTOCK VACCINES
  • 6.2.1 BOVINE VACCINES
    • 6.2.1.1 Increasing demand for meat and milk to drive market
  • 6.2.2 SMALL RUMINANT VACCINES
    • 6.2.2.1 Increased livestock population and favorable government initiatives to propel market growth
• 6.3 PORCINE VACCINES
  • 6.3.1 GROWING AWARENESS ABOUT ANIMAL VACCINATION TO SUPPORT MARKET GROWTH
• 6.4 POULTRY VACCINES
  • 6.4.1 HIGH NEED FOR PROTEIN IN DAILY DIET TO AUGMENT MARKET GROWTH
• 6.5 COMPANION ANIMAL VACCINES
  • 6.5.1 CANINE VACCINES
    • 6.5.1.1 Increasing number of pet dogs and growing prevalence of zoonotic diseases to spur market growth
  • 6.5.2 FELINE VACCINES
    • 6.5.2.1 Rising adoption of cats and growing need for better veterinary care to boost market growth
• 6.6 AQUACULTURE VACCINES
  • 6.6.1 INCREASED POPULARITY OF COMMERCIAL FISH FARMING TO FUEL MARKET GROWTH
• 6.7 OTHER VETERINARY VACCINES

7 VETERINARY VACCINES MARKET, BY DISEASE

• 7.1 INTRODUCTION
• 7.2 LIVESTOCK DISEASES
  • 7.2.1 BOVINE DISEASES
    • 7.2.1.1 Favorable government programs and increased awareness about animal health in emerging economies to aid market growth
  • 7.2.2 SMALL RUMINANT DISEASES
    • 7.2.2.1 New vaccine formulations and improved delivery methods to propel vaccine demand for small ruminants
• 7.3 PORCINE DISEASES
  • 7.3.1 INCREASED FOCUS ON LARGE-SCALE INDUSTRIAL BREEDING OF PIGS TO AID MARKET GROWTH
• 7.4 POULTRY DISEASES
  • 7.4.1 ONGOING RISK OF AVIAN INFLUENZA OUTBREAKS TO SPUR NEED FOR POULTRY VACCINES
• 7.5 COMPANION ANIMAL DISEASES
  • 7.5.1 CANINE DISEASES
    • 7.5.1.1 Rise in pet ownership in emerging economies to boost market growth
  • 7.5.2 FELINE DISEASES
    • 7.5.2.1 Rise in cat population in urban areas to drive demand for feline disease management programs
• 7.6 AQUACULTURE DISEASES
  • 7.6.1 NEED FOR PREVENTIVE HEALTHCARE AND BIOSECURITY TO SUPPORT MARKET GROWTH
• 7.7 OTHER VETERINARY DISEASES

8 VETERINARY VACCINES MARKET, BY TECHNOLOGY

• 8.1 INTRODUCTION
• 8.2 LIVE ATTENUATED VACCINES
  • 8.2.1 EASE OF ADMINISTRATION AND LONG-TERM IMMUNITY TO SUPPORT MARKET GROWTH
• 8.3 INACTIVATED VACCINES
  • 8.3.1 NEED TO DEVELOP ARTIFICIAL IMMUNITY FROM NON-LIVING PATHOGENS TO DRIVE MARKET
• 8.4 TOXOID VACCINES
  • 8.4.1 TOXOID VACCINES TO STIMULATE IMMUNE SYSTEM AND PROTECT ANIMALS FROM BACTERIAL TOXINS
• 8.5 RECOMBINANT VACCINES
  • 8.5.1 BETTER STABILITY, HIGHER SAFETY, AND NO POST-VACCINATION REACTIONS TO SUPPORT VACCINE ADOPTION
• 8.6 OTHER VACCINE TECHNOLOGIES

9 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION

• 9.1 INTRODUCTION
• 9.2 SUBCUTANEOUS ROUTE OF ADMINISTRATION
  • 9.2.1 EASE OF ADMINISTRATION, REDUCED PAIN, AND LOWER RISK OF TISSUE DAMAGE TO AID MARKET GROWTH
• 9.3 INTRAMUSCULAR ROUTE OF ADMINISTRATION
  • 9.3.1 BETTER IMMUNE RESPONSE AND LOWER RATE OF INJECTION-SITE REACTIONS TO AUGMENT MARKET GROWTH
• 9.4 ORAL ROUTE OF ADMINISTRATION
  • 9.4.1 COST-EFFECTIVENESS, INCREASED SAFETY, AND HIGH PATIENT ACCEPTABILITY TO SUPPORT MARKET GROWTH
• 9.5 INTRANASAL/SPRAY ROUTE OF ADMINISTRATION
  • 9.5.1 COST-EFFECTIVENESS AND RAPID ABSORPTION OF MEDICINE TO AID IN MASS VACCINATION
• 9.6 INTRAOCULAR ROUTE OF ADMINISTRATION
  • 9.6.1 SIMPLE ADMINISTRATION OF VACCINES IN LARGE-SCALE FARMING OPERATIONS TO AID MARKET GROWTH
• 9.7 OTHER ROUTES OF ADMINISTRATION

10 VETERINARY VACCINES MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 VETERINARY HOSPITALS
  • 10.2.1 GROWING AWARENESS ABOUT ANIMAL HEALTH AND INCREASING VETERINARY EXPENDITURE BY PET OWNERS TO DRIVE MARKET
• 10.3 VETERINARY CLINICS
  • 10.3.1 RISING NUMBER OF PET VISITS TO PRIVATE CLINICS TO SPUR MARKET GROWTH
• 10.4 OTHER END USERS

11 VETERINARY VACCINES MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 ASIA PACIFIC
  • 11.2.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.2.2 CHINA
    • 11.2.2.1 Increasing companion animal population and growing incidence of zoonotic diseases to drive market
  • 11.2.3 JAPAN
    • 11.2.3.1 High consumption of animal-derived products and increased pet health expenditure to propel market growth
  • 11.2.4 INDIA
    • 11.2.4.1 Growth in poultry industry and high demand for dairy products to augment market growth
  • 11.2.5 AUSTRALIA
    • 11.2.5.1 Increase in per capita income and rise in meat consumption to aid market growth
  • 11.2.6 SOUTH KOREA
    • 11.2.6.1 High demand for animal protein and favorable government subsidies for meat production to spur market growth
  • 11.2.7 NEW ZEALAND
    • 11.2.7.1 Favorable government initiatives and increased incidence of livestock diseases to boost market growth
  • 11.2.8 REST OF ASIA PACIFIC
• 11.3 NORTH AMERICA
  • 11.3.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.3.2 US
    • 11.3.2.1 US to dominate North American veterinary vaccines market during forecast period
  • 11.3.3 CANADA
    • 11.3.3.1 Rising pet ownership and increasing chicken consumption to drive demand for veterinary vaccines
• 11.4 EUROPE
  • 11.4.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.4.2 GERMANY
    • 11.4.2.1 Increased poultry consumption and high pet healthcare expenditure to drive market
  • 11.4.3 UK
    • 11.4.3.1 Rising adoption of pets to augment market growth
  • 11.4.4 FRANCE
    • 11.4.4.1 Rising companion animal and livestock population to boost market growth
  • 11.4.5 ITALY
    • 11.4.5.1 Better availability of pet products through large-scale outlets to augment market growth
  • 11.4.6 SPAIN
    • 11.4.6.1 Increase in veterinary practices and willingness to spend on animal healthcare to drive market
  • 11.4.7 NETHERLANDS
    • 11.4.7.1 High demand for meat and increased pressure on sustainable farming practices to fuel market growth
  • 11.4.8 REST OF EUROPE
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Well-established livestock industry to promote market growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Focus on pork and poultry meat production to fuel market growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Kingdom of Saudi Arabia
      • 11.6.2.1.1 Favorable government initiatives for better animal health infrastructure to propel market growth
    • 11.6.2.2 UAE
      • 11.6.2.2.1 Favorable government initiatives to safeguard national livestock population and support sustainable agriculture
    • 11.6.2.3 Rest of GCC countries
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
• 12.3 REVENUE ANALYSIS, 2019-2023
• 12.4 MARKET SHARE ANALYSIS, 2023
  • 12.4.1 RANKING OF KEY MARKET PLAYERS, 2O23
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Type footprint
    • 12.5.5.4 Disease footprint
    • 12.5.5.5 Technology footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 12.7 BRAND/PRODUCT COMPARISON
• 12.8 R&D EXPENDITURE OF KEY PLAYERS
• 12.9 COMPANY VALUATION & FINANCIAL METRICS
  • 12.9.1 FINANCIAL METRICS
  • 12.9.2 COMPANY VALUATION
• 12.10 COMPETITIVE SCENARIO
  • 12.10.1 PRODUCT LAUNCHES & APPROVALS
  • 12.10.2 DEALS
  • 12.10.3 EXPANSIONS
  • 12.10.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 MERCK & CO., INC.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches & approvals
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Expansions
      • 13.1.1.3.4 Other developments
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 ZOETIS
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches
      • 13.1.2.3.2 Deals
      • 13.1.2.3.3 Expansions
      • 13.1.2.3.4 Other developments
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches
      • 13.1.3.3.2 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 ELANCO
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
  • 13.1.5 CEVA
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Deals
      • 13.1.5.3.2 Expansions
  • 13.1.6 VIRBAC
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product launches
      • 13.1.6.3.2 Deals
      • 13.1.6.3.3 Expansions
      • 13.1.6.3.4 Other developments
  • 13.1.7 PHIBRO ANIMAL HEALTH CORPORATION
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
  • 13.1.8 HESTER BIOSCIENCES LIMITED
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Deals
  • 13.1.9 NEOGEN CORPORATION
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Deals
  • 13.1.10 HIPRA
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Product launches
  • 13.1.11 BIOGENESIS BAGO
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Expansions
  • 13.1.12 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Deals
  • 13.1.13 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
  • 13.1.14 JINYU BIO-TECHNOLOGY CO., LTD.
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Product approvals
  • 13.1.15 VAXXINOVA INTERNATIONAL B.V.
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Product approvals
      • 13.1.15.3.2 Expansions
• 13.2 OTHER COMPANIES
  • 13.2.1 ENDOVAC ANIMAL HEALTH
  • 13.2.2 BRILLIANT BIO PHARMA
  • 13.2.3 APTIMMUNE
  • 13.2.4 INDIAN IMMUNOLOGICALS LTD.
  • 13.2.5 TORIGEN PHARMACEUTICALS INC.
  • 13.2.6 INTAS PHARMACEUTICALS LTD.
  • 13.2.7 OUROFINO ANIMAL HEALTH
  • 13.2.8 BIOVAC LTD.
  • 13.2.9 LABORATOIRE LCV
  • 13.2.10 KYORITSU SEIYAKU CORPORATION

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS

관련자료